215 related articles for article (PubMed ID: 22257609)
1. [Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia].
Sanz MÁ; Vicente García V; Fernández A; López MF; Grande C; Jarque I; Martínez R; Mingot ME; Monteagudo E; Ribera JM; Valcárcel D; ;
Med Clin (Barc); 2012 Mar; 138(6):261.e1-261.e17. PubMed ID: 22257609
[TBL] [Abstract][Full Text] [Related]
2. Management of immune thrombocytopenia in elderly patients.
Lucchini E; Fanin R; Cooper N; Zaja F
Eur J Intern Med; 2018 Dec; 58():70-76. PubMed ID: 30274902
[TBL] [Abstract][Full Text] [Related]
3. Immune thrombocytopenic purpura in pregnancy.
Gernsheimer T; McCrae KR
Curr Opin Hematol; 2007 Sep; 14(5):574-80. PubMed ID: 17934366
[TBL] [Abstract][Full Text] [Related]
4. Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.
Tamary H; Roganovic J; Chitlur M; Nugent DJ
Ann Hematol; 2010 Jul; 89 Suppl 1(Suppl 1):5-10. PubMed ID: 20358200
[TBL] [Abstract][Full Text] [Related]
5. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
[TBL] [Abstract][Full Text] [Related]
6. [New treatment options for primary immune thrombocytopenia].
Gudbrandsdottir S; Frederiksen H; Birgens HS; Nielsen CH; Nielsen OJ; Stentoft J; Hasselbalch HC
Ugeskr Laeger; 2011 Jan; 173(4):271-4. PubMed ID: 21262171
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic options for immune thrombocytopenia.
Schipperus M; Fijnheer R
Neth J Med; 2011; 69(11):480-5. PubMed ID: 22173361
[TBL] [Abstract][Full Text] [Related]
8. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].
Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T
Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804
[No Abstract] [Full Text] [Related]
9. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
[No Abstract] [Full Text] [Related]
10. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
Stasi R; Evangelista ML; Stipa E; Buccisano F; Venditti A; Amadori S
Thromb Haemost; 2008 Jan; 99(1):4-13. PubMed ID: 18217129
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
[No Abstract] [Full Text] [Related]
12. Immune thrombocytopenia -- what are the new treatment options?
Hallam S; Provan D; Newland AC
Expert Opin Biol Ther; 2013 Aug; 13(8):1173-85. PubMed ID: 23682685
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag with i.v. immunoglobulin for safe splenectomy in refractory immune thrombocytopenia.
Kanno M; Onoda T; Meguro T; Sato H; Mitsui T
Pediatr Int; 2018 Feb; 60(2):191-192. PubMed ID: 29271533
[No Abstract] [Full Text] [Related]
14. What is publication? The case of eltrombopag.
Benham L; Guo L; Turner R
Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
[No Abstract] [Full Text] [Related]
15. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
[No Abstract] [Full Text] [Related]
16. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
17. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
18. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Godeau B;
Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
[No Abstract] [Full Text] [Related]
19. Moving towards a new era in the management of chronic immune thrombocytopenia.
Wadenvik H; Olsson B
Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
